TABLE 2.
Details of adverse events during VIT. The percentages refer to the total number of adverse events (n = 93). Missing data are not explicitly stated in the table. Classification according to Ring and Messmer18
| Grade I | Grade II | Grade III | total | |
|---|---|---|---|---|
| Adverse events, n (%) | 54 (58.1) | 38 (40.9) | 1 (1.1) | 93 (100.0) |
| Up‐dosing protocol, n (%) | ||||
| Conventional | 2 (2.2) | 3 (3.2) | 0 (0.0) | 5 (5.4) |
| Cluster, ultrarush | 27 (29.0) | 17 (18.3) | 1 (1.1) | 45 (48.4) |
| Rush | 23 (24.7) | 16 (17.2) | 0 (0.0) | 39 (41.9) |
| Premedication, n (%) | ||||
| No | 21 (22.6) | 15 (16.1) | 0 (0.0) | 36 (38.7) |
| Yes | 33 (35.5) | 23 (24.7) | 1 (1.1) | 57 (61.3) |
| Tryptase level, n (%) | ||||
| >11.4 µg/L | 7 (7.5) | 5 (5.4) | 1 (1.1) | 13 (14.0) |
| Treatment with β‐blockers and/or ACEI, n (%) | ||||
| No | 43 (46.2) | 30 (32.3) | 1 (1.1) | 74 (79.6) |
| β‐blockers | 1 (1.1) | 3 (3.2) | 0 (0.0) | 4 (4.3) |
| ACEI | 8 (8.6) | 5 (5.4) | 0 (0.0) | 13 (14.0) |
| β‐blockers and ACEI | 2 (2.2) | 0 (0.0) | 0 (0.0) | 2 (2.2) |